Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia

Abstract

Letter to Blood| February 23, 2023 Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia Clinical Trials & Observations Graça M. Dores, Graça M. Dores 1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0002-3985-2935 Search for other works by this author on: This Site PubMed Google Scholar Martha S. Linet, Martha S. Linet 1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0002-1687-5587 Search for other works by this author on: This Site PubMed Google Scholar Rochelle E. Curtis, Rochelle E. Curtis 1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD Search for other works by this author on: This Site PubMed Google Scholar Lindsay M. Morton Lindsay M. Morton 1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD https://orcid.org/0000-0001-9767-2310 Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (8): 951–955. https://doi.org/10.1182/blood.2022018051 Article history Submitted: August 10, 2022 Accepted: November 10, 2022 Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Graça M. Dores, Martha S. Linet, Rochelle E. Curtis, Lindsay M. Morton; Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia. Blood 2023; 141 (8): 951–955. doi: https://doi.org/10.1182/blood.2022018051 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia, Myeloid Neoplasia TO THE EDITOR: The risks of therapy-related myelodysplastic syndromes and acute myeloid leukemia (t-MDS/AML) are well-studied1-3; however, few studies have quantified risks of less common therapy-related hematopoietic neoplasms (t-HNs) in chemotherapy-exposed populations. Hindering the assessment of these t-HNs is their rarity, which requires the study of large numbers of patient populations who are at risk. We therefore sought to systematically quantify the risks for several t-HNs, including chronic myeloid leukemia (t-CML), classical myeloproliferative neoplasms (t-cMPNs), chronic myelomonocytic leukemia (t-CMML), and acute lymphoblastic leukemia/lymphoma (tr-ALL) (supplemental Table 1; available on Blood website). We evaluated these t-HNs after a broad spectrum of first primary cancers among adults treated with initial chemotherapy leveraging US population-based cancer registries. In the 17 Surveillance, Epidemiology, and End Results (SEER-17) program areas covering ∼28% of the US population, we identified a cohort of adults (20-84 years)...